Nano4Imaging GmbH

Nano4Imaging GmbH is a medtech company specializing in interventional MRI (iMRI) solutions that transform MRI from a purely diagnostic tool into a fully capable interventional platform. The company develops the trackr. technology ecosystem, which comprises three integrated components: EmeryGlide (an FDA-cleared, MRI-conditional, metal-free guidewire with nanoparticle coating for real-time visualization across all imaging modalities); Magnafy (an advanced multimodal nanoparticle composite applicable to any device for discrete marker visualization in MRI and CT); and trackr.ai (a proprietary deep learning algorithm that provides real-time, radiation-free catheter navigation with GPS-like tracking capability). The platform enables physicians to perform safe, precise interventions without ionizing radiation or nephrotoxic contrast agents, supporting diagnostic and therapeutic procedures in cardiology, particularly right and left heart catheterization and congenital heart disease management. Clinical evidence documents over 200 patients treated with zero procedural complications. The company has demonstrated 250 successful right heart catheterizations for pulmonary pressure assessment. Nano4Imaging collaborates with leading healthcare institutions across Europe and North America. The company was recognized among the top 3% European innovators by the European Innovation Council and received an Accelerator Grant for breakthrough technology potential. EmeryGlide is the world's first FDA-cleared MRI-compatible guidewire and is labeled MR conditional per ASTM standards F2182, F2052, F2053, and F2213. The company continuously expands its portfolio with MRI-compatible catheters and accessory tools.